title: Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine.
abstract: Distinct lines of evidence indicate that glutamate plays a primary role in modulating cognitive functions. Notably, competitive glutamate receptor antagonists acting at ionotropic N-methyl-d-aspartate (NMDA) or metabotropic glutamate 5 (mGlu5) receptors impair cognitive performance. Conversely, nicotine and other psychostimulants stimulate glutamatergic mechanisms and can act as cognitive enhancers. Hence we analysed the role of glutamate in performance of an attentional task and in nicotine-induced enhancement of attention by using the rodent five-choice serial reaction time task (5-CSRTT). Rats were trained to criterion performance and were then pre-dosed with either vehicle, the NMDA receptor antagonist (+)3-(2-carboxypiperazin-4-propyl)-1-propenyl-1-phosphonic acid (CPP, 0.3-2.0 mg/kg) or the mGlu5 antagonist 2-methyl-6-phenylethynyl-pyridine (MPEP, 1.0-9.0 mg/kg) and challenged with nicotine (0.2 mg/kg). Nicotine improved attentional performance, an effect that was weakened by doses of CPP that themselves had little impact on performance; importantly, CPP dose-dependently blunted the ability of nicotine to improve response accuracy, the major measure of signal detection in the paradigm. MPEP dose-dependently impaired signal detection under conditions with a high attentional load, an effect that was reversed by nicotine; thus, MPEP did not block nicotine-induced attentional enhancement. Co-administration of either CPP or MPEP with nicotine also produced a general slowing of performance characterised by increases in omission errors and response latencies and reduced anticipatory responding. It is concluded that activation of NMDA receptors may be an important determinant of the effects of nicotine in the 5-CSRTT. Stimulation of nicotinic receptors may also reverse attentional deficits associated with the impaired function of the glutamate network.
authors.affiliation: Section of Behavioural Pharmacology P049, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK.
authors.forename: Davide
authors.initials: D
authors.lastname: Quarta
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Naylor
authors.forename: Hannah V
authors.initials: HV
authors.lastname: Morris
authors.forename: Swital
authors.initials: S
authors.lastname: Patel
authors.forename: Rachel F
authors.initials: RF
authors.lastname: Genn
authors.forename: Ian P
authors.initials: IP
authors.lastname: Stolerman
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001288:Attention / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects; D002755:Choice Behavior / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D008297:Male; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D013647:Task Performance and Analysis
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018722:Nicotinic Agonists; D010879:Piperazines; D011725:Pyridines; D009538:Nicotine; C121465:6-methyl-2-(phenylethynyl)pyridine; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid